Always happy to hear your feedback.
©2021 Impeka WordPress Theme

Exciting News: Clever-Access and Assignity Merge!
After two years of successful collaboration that has greatly benefited our clients, we are thrilled to announce that Clever-Access and Assignity have decided to take our partnership to the next level.
See their website! 
A New Chapter Begins
Today marks a significant milestone as we merge to form a single legal entity under the Clever-Access brand. This strategic move is designed to enhance clarity and strengthen our unified approach, bringing together a cohesive team of over 80 talented colleagues.
What This Means for Our Clients
Streamlined Services: By combining our expertise, we will streamline our high-quality services, ensuring that our clients receive even better solutions tailored to their needs.
Enhanced Market Presence: Our merger will bolster our market presence, allowing us to serve our clients more effectively and expand our reach globally.
Looking Ahead
We are incredibly excited about this new chapter and the opportunities it brings. Together, we will continue to innovate and deliver exceptional value to our clients as we embark on this great adventure. Thank you for your continued support, and we look forward to what the future holds!
#CleverAccess #Assignity #Merger #HTA #HEOR #MarketAccess #ClientSuccess
 

Our Team
of Experts

Clever-Access was co-founded by a team of top-class experts in life science consulting, leveraging global and multidisciplinary expertise, for a comprehensive offering.

After more than a decade of working together, we have decided to create our own company, to combine our passion for methodology and challenges, our highly technical and strategic skills, and our will to collaborate in an authentic and trustful environment.

Want to know more?

Aurélie Millier

Senior Director HEOR & Market Access

I have a statistical background, and PhD in health economics.

After an experience as a biostatistician in a CRO, in 2008, I joined Creativ-Ceutical, another Market Access consulting company. Over 14 years, I progressed from baby analyst to Vice-President of the HEOR group, leading several strategic departments such as the Evidence Synthesis and the HTA departments.

I developed specific skills in statistics applied to health and economic analysis, developed HEOR plans, designed dozens of health economic models, managed even more HTA dossiers in diverse countries and enjoyed the coordination of strategic launches for global teams.

I discovered my passion about team management, and happily grew a team of more than 50 talented and professional people.

I also teach health economics in different Universities, master and post-graduate level, where I continue to share my knowledge, and best tips.

Privately, I practice jazz roots dancing, to feed my dynamism and express my
improvisational skills, but also Taiji Quan, to work on integration and stability. 

I also speak with my dog… tell me if you’re interested !

Biostatistician by background, I hold a PhD in Health economics.

I joined Creativ-Ceutical for my end-of-studies internship and over 12 years, I
progressively climbed the stairs up to Vice-President of the HEOR group.

I was supervising three highly technical departments, including Modelling, Data analytics and Patient-Centered Research departments.

My area of predilection is health economic modelling. I worked 6 years as a Modeller and then led the Modelling team for more than 3 years.

Privately, I do not have major hobbies but an infinity of small ones! With no order of
preference: Knitting, Sewing, Bonsai, Video Edition, Canvas, Video games, crafting fakeaxes or shield, Soap,…

Any new idea is welcome!

Emilie Clay

Co-founder, Head of HEOR

Emilie Clay

CO-FOUNDER

Biostatistician by background, I hold a PhD in Health economics.

I joined Creativ-Ceutical for my end-of-studies internship and over 12 years, I
progressively climbed the stairs up to Vice-President of the HEOR group.

I was supervising three highly technical departments, including Modelling, Data analytics and Patient-Centered Research departments.

My area of predilection is health economic modelling. I worked 6 years as a Modeller and then led the Modelling team for more than 3 years.

Privately, I do not have major hobbies but an infinity of small ones! With no order of
preference: Knitting, Sewing, Bonsai, Video Edition, Canvas, Video games, crafting fakeaxes or shield, Soap,…

Any new idea is welcome!

Agathe Leray

Co-founder
Head of Business Development

My 14-year career in healthcare consultancies has focused on business strategy development and deployment with an emphasis on Market Access, Health Technology Assessment and Health Economics and Outcomes Research.

I am a Biologist by training, and I began my career in an international CRO as an international Business Developer, supporting clients optimizing their clinical trials and then spent several years with Creativ-Ceutical, a consultancy firm expert in Market Access and HEOR where I started as Business Development Director and then held Business Development and Quality Assurance Vice president role. As member of the executive board, I was responsible for the strategic direction and growth of the business.

I have led and fostered international multidisciplinary teams in both Clinical Research Organizations (CRO) and Consultancy, to support strategic and commercial decisions.

With a keen understanding of client needs, I have proven success in deploying commercially viable solutions to meet the changing demands of the Pharmaceutical and Biotech industry.

Privately, I practice yoga almost every day (thanks to Aurélie), I go for a run as soon as I can, and I love exploring new fields related to nature and music.

We’re also working with external scientific advisors:

Mira Pavlovic

Mira Pavlovic


External Consultant
Clinical, Regulatory & HTA

I am a founder of Medicines Development and Training (MDT) services. I am specialist in dermatology (currently Head of Sabouraud Research and Treatment Center for Hair and Skin diseases at Saint-Louis Hospital in Paris), in regulatory science and in HTA for reimbursement purposes with more than 25 years of experience as an expert in clinical and regulatory field. For 12 years I was serving as a Head of Scientific Advice at the French Medicines Agency (ANSM) and was member of several working parties at the EMA). As SAWP Vice-Chair, I was involved in the review of more than 1000 scientific advices in 10 years. In 2010 I joined the Haute Autorité de Santé (HAS), France, as Deputy Director for Health Technology Assessment, and was in charge of European activities related to relative effectiveness assessment, in particular those coordinated by the EUnetHTA, such as early dialogues with developers and methodology of assessment for reimbursement purposes. I also coordinated the SEED (Shaping European Early Dialogues) project financed by European Commission to support early dialogues between developers and HTA bodies as a permanent activity in Europe. Since September 2015 I consult on clinical drug development strategies and act as member of the NDA Advisory Board. My main research areas cover endpoints for marketing authorization/relative effectiveness assessment and bridging of efficacy - effectiveness gap in product development.
Samuel Aballéa

Samuel Aballéa


External Consultant
HEOR

I worked for 20 years as a consultant in HEOR. Before founding Innovlntel with Pr Toumi, I was Senior Vice-President and Chief Scientific Officer as Creativ-Ceutical, where I managed or directed many health economic and epidemiological research projects including the development of core models, multi-country patient preference studies, network meta-analyses of clinical trials and RWE studies. My expertise focuses on the application of quantitative methods in the context of the value assessment of health care interventions. I have authored near 100 journal publications in the field of HEOR. I am currently based in the Netherlands and previously worked in the UK and France. I hold a post-graduate degree in Biostatistics (ENSAI, France), an MSc in Health Economics (University of York, UK) and a PhD in Economic Sciences (University of Lyon 1, France).
Joseph L. Boswelll

Joseph L. Boswelll


External Consultant
US

I am a founder of GenMAV.I have more than 25 years of experience in Market Access and HEOR consulting. I was heading up Business Development for Avalere Health in Washington DC for more than 12 years. I also worked in the Pharma (Johnson & Johnson and Wyeth-Ayerst) and Biotech industry. My main area of expertise are Value & Evidence Continuum, Patient, Payers & other Stakeholders Engagement and Digital Platforms.

We’re working with :

Lylia Chachoua

Lylia Chachoua


Senior Consultant,
Market Access

Over the last years, I gained significant experience in Strategic Market Access, and Patient-Centered Research in the consulting world, with an in-depth knowledge of payer and HTA requirements. I mostly contribute to European and Global projects, including HTA submission, value communication, strategic positioning, I develop value propositions, value dossiers, dossier submission, landscape assessments, as well as primary research and stakeholders advisory board management. I also have experience in Patient-Centered Research; I recently defended my PhD on the role of health preference information in informing the evaluation of health technologies in France and have significant experience in Discrete Choice Experiment.
Olivier Cristeau

Olivier Cristeau


Senior Consultant
HEOR

Before joining Clever-Access, I worked for 15 years as a consultant in HEOR, with a focus on HE modelling. I work on economic evaluations within a decision-making framework (core cost-effectiveness, budget impact and epidemiological models; cost-calculator, net present value, impact of inaction), complex modelling including Markov transition models, discrete event simulations, dynamic transmission models, static population models, decision trees, micro-simulations, data calibration. I also have expertise in IT solutions and development of value-communication tools (KAM, RIR).
Samuel Aballéa

Samuel Aballéa


External Consultant
HEOR

I worked for 20 years as a consultant in HEOR. Before founding Innovlntel with Pr Toumi, I was Senior Vice-President and Chief Scientific Officer as Creativ-Ceutical, where I managed or directed many health economic and epidemiological research projects including the development of core models, multi-country patient preference studies, network meta-analyses of clinical trials and RWE studies. My expertise focuses on the application of quantitative methods in the context of the value assessment of health care interventions. I have authored near 100 journal publications in the field of HEOR. I am currently based in the Netherlands and previously worked in the UK and France. I hold a post-graduate degree in Biostatistics (ENSAI, France), an MSc in Health Economics (University of York, UK) and a PhD in Economic Sciences (University of Lyon 1, France).
Mira Pavlovic

Mira Pavlovic


External Consultant
Clinical, Regulatory & HTA

I am a founder of Medicines Development and Training (MDT) services. I am specialist in dermatology (currently Head of Sabouraud Research and Treatment Center for Hair and Skin diseases at Saint-Louis Hospital in Paris), in regulatory science and in HTA for reimbursement purposes with more than 25 years of experience as an expert in clinical and regulatory field. For 12 years I was serving as a Head of Scientific Advice at the French Medicines Agency (ANSM) and was member of several working parties at the EMA). As SAWP Vice-Chair, I was involved in the review of more than 1000 scientific advices in 10 years. In 2010 I joined the Haute Autorité de Santé (HAS), France, as Deputy Director for Health Technology Assessment, and was in charge of European activities related to relative effectiveness assessment, in particular those coordinated by the EUnetHTA, such as early dialogues with developers and methodology of assessment for reimbursement purposes. I also coordinated the SEED (Shaping European Early Dialogues) project financed by European Commission to support early dialogues between developers and HTA bodies as a permanent activity in Europe. Since September 2015 I consult on clinical drug development strategies and act as member of the NDA Advisory Board. My main research areas cover endpoints for marketing authorization/relative effectiveness assessment and bridging of efficacy - effectiveness gap in product development.
Joseph L. Boswelll

Joseph L. Boswelll


External Consultant
US

I am a founder of GenMAV.I have more than 25 years of experience in Market Access and HEOR consulting. I was heading up Business Development for Avalere Health in Washington DC for more than 12 years. I also worked in the Pharma (Johnson & Johnson and Wyeth-Ayerst) and Biotech industry. My main area of expertise are Value & Evidence Continuum, Patient, Payers & other Stakeholders Engagement and Digital Platforms.

We have collectively defined important values that will  accompany the development of Clever-Access

Trust & Integrity

  • Now more than ever, we are expected to do the right things and do them well, from entrusting to safeguard one’s personal data to requiring a strong stance on quality. 
  • Integrity is not defined by what you do when no one is looking. Rather, what you do when no one is looking is defined by your integrity.
  • External trust as well as trust internally: “Lose money and I will forgive you. Lose even a shred of reputation and I will be ruthless”

Service & Commitment

  • Obvious for a consulting company, no? But for us, it is a strong belief.
  • “Put purpose before profit, and conviction over compliance.”

Ambition & Efficiency

  • Now more than ever, we are expected to do the right things and do them well, from entrusting to safeguard one’s personal data to requiring a strong stance on quality. 
  • Integrity is not defined by what you do when no one is looking. Rather, what you do when no one is looking is defined by your integrity.
  • External trust as well as trust internally: “Lose money and I will forgive you. Lose even a shred of reputation and I will be ruthless”

Respect & Responsibility

  • For us, respect comprises respect both as a person, with the creation of a space where each member of the group is valuable, and respect for professional achievement. Respect increases productivity, collaboration, and satisfaction. 
  • And responsibility, defined as ownership and commitment, is the price of respect.

Well-being & Solidarity

  • We, as employers, are concerned with the well-being of the employees.
  • It should not be an isolated initiative, rather an integrated approach that encompasses several dimensions.

Our company has been awarded a silver medal in recognition of sustainability achievement!

We stand among the top 25% of companies assessed by EcoVadis.

Our Services

We generate value to our clients thanks to our team combining strategic advice expertise with robust technical capabilities.

Check Our Services

Large publication history

See how active we have been when it comes to dissemination of information!

Check More
Let's be clever together !
Close